1
|
Deconinck E, Raimondo M, Borioni A, Grange Y, Rebière H, Mihailova A, Bøyum O, Maurin JK, Pioruńska-Sędłak K, Olsen LS, Acevska J, Brezovska K, Rundlöf T, Portela MJ, Meieranz S, Miquel M, Bertrand M. Clustering of Tadalafil API Samples According to their Manufacturer in the Context of API Falsification Detection. J Pharm Sci 2023; 112:2834-2842. [PMID: 37220827 DOI: 10.1016/j.xphs.2023.05.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2023] [Revised: 05/17/2023] [Accepted: 05/17/2023] [Indexed: 05/25/2023]
Abstract
This paper reports the results of the active pharmaceutical ingredient (API) fingerprint study, organised by the General European Official Medicines Control Laboratory Network (GEON), on tadalafil. A classical market surveillance study, evaluating compliance to the European Pharmacopoeia, was combined with a fingerprint study, the latter to obtain characteristic data for the different manufacturers, allowing the network laboratories to conduct authenticity tests for future samples, as well as to detect substandard and falsified samples. In total, 46 tadalafil API samples from 13 different manufacturers were collected. For all samples fingerprint data was collected through analysis of impurities and residual solvents, mass spectrometric screening, X-ray powder diffraction and proton nuclear magnetic resonance (1H-NMR). Chemometric analysis revealed that all manufacturers could be characterised based on the impurity, residual solvent and 1H-NMR data. Future suspicious samples in the network will therefore be analysed with these techniques in order to attribute the sample to one of the manufacturers. If the sample cannot be attributed, a more profound investigation will be necessary to reveal the origin of the sample. In cases where the suspect sample is claimed to be from one of the manufacturers included in this study, analysis can be limited to the test distinguishing that manufacturer.
Collapse
Affiliation(s)
- E Deconinck
- OMCL Active Pharmaceutical Ingredient (API) Working Group, GEON Network, EDQM - Council of Europe, 7 allée Kastner, CS 30026, F-67081, Strasbourg, France; Scientific Direction Chemical and Physical Health Risks, Service of Medicines and Health Products, Sciensano, J. Wytsmanstraat 14, B-1050, Brussels, Belgium.
| | - M Raimondo
- OMCL Active Pharmaceutical Ingredient (API) Working Group, GEON Network, EDQM - Council of Europe, 7 allée Kastner, CS 30026, F-67081, Strasbourg, France; Istituto Superiore di Sanità, National Centre for the Control and Evaluation of Medicines, Chemical Medicines Unit, viale Regina Elena 299, 00161, Rome, Italy
| | - A Borioni
- Istituto Superiore di Sanità, National Centre for the Control and Evaluation of Medicines, Chemical Medicines Unit, viale Regina Elena 299, 00161, Rome, Italy
| | - Y Grange
- OMCL Active Pharmaceutical Ingredient (API) Working Group, GEON Network, EDQM - Council of Europe, 7 allée Kastner, CS 30026, F-67081, Strasbourg, France; French National Agency for Medicines and Health Products Safety (ANSM), Laboratory Controls Division, 635 Rue de la Garenne, F-34740, Vendargues, France
| | - H Rebière
- French National Agency for Medicines and Health Products Safety (ANSM), Laboratory Controls Division, 635 Rue de la Garenne, F-34740, Vendargues, France
| | - A Mihailova
- OMCL Active Pharmaceutical Ingredient (API) Working Group, GEON Network, EDQM - Council of Europe, 7 allée Kastner, CS 30026, F-67081, Strasbourg, France; Norwegian Medicines Agency, Grensesvingen 26, NO-0663, Oslo, Norway
| | - O Bøyum
- Norwegian Medicines Agency, Grensesvingen 26, NO-0663, Oslo, Norway
| | - J K Maurin
- National Medicines Institute, 30/34 Chelmska str., 00-725, Warsaw, Poland
| | - K Pioruńska-Sędłak
- National Medicines Institute, 30/34 Chelmska str., 00-725, Warsaw, Poland
| | - L Stengelshøj Olsen
- Danish Medicines Agency, Medicines Control and Inspection Division, Axel Heides Gade 1, 2300, Copenhagen S, Denmark
| | - J Acevska
- OMCL Active Pharmaceutical Ingredient (API) Working Group, GEON Network, EDQM - Council of Europe, 7 allée Kastner, CS 30026, F-67081, Strasbourg, France; Center for Drug Quality Control, Institute of applied chemistry and pharmaceutical analysis, Faculty of Pharmacy, University Ss. Cyril and Methodius, Majka Tereza 47, POB 36, 1000, Skopje, Republic of North Macedonia
| | - K Brezovska
- Center for Drug Quality Control, Institute of applied chemistry and pharmaceutical analysis, Faculty of Pharmacy, University Ss. Cyril and Methodius, Majka Tereza 47, POB 36, 1000, Skopje, Republic of North Macedonia
| | - T Rundlöf
- OMCL Active Pharmaceutical Ingredient (API) Working Group, GEON Network, EDQM - Council of Europe, 7 allée Kastner, CS 30026, F-67081, Strasbourg, France; Swedish Medical Products Agency, Laboratory, Box 26, Dag Hammarskjölds väg 42, SE-751 03, Uppsala, Sweden
| | - M J Portela
- OMCL Active Pharmaceutical Ingredient (API) Working Group, GEON Network, EDQM - Council of Europe, 7 allée Kastner, CS 30026, F-67081, Strasbourg, France; INFARMED - Autoridade Nacional do Medicamento e Produtos de Saúde, I.P. Parque de Saúde de Lisboa - Avenida do Brasil, 53, 1749-004, Lisboa, Portugal
| | - S Meieranz
- OMCL Active Pharmaceutical Ingredient (API) Working Group, GEON Network, EDQM - Council of Europe, 7 allée Kastner, CS 30026, F-67081, Strasbourg, France; Landeslabor Berlin-Brandenburg - Institut für Lebensmittel, Arzneimittel, Tierseuchen und Umwelt, Rudower Chaussee 39, 12489, Berlin, Germany
| | - M Miquel
- OMCL Active Pharmaceutical Ingredient (API) Working Group, GEON Network, EDQM - Council of Europe, 7 allée Kastner, CS 30026, F-67081, Strasbourg, France
| | - M Bertrand
- OMCL Active Pharmaceutical Ingredient (API) Working Group, GEON Network, EDQM - Council of Europe, 7 allée Kastner, CS 30026, F-67081, Strasbourg, France
| |
Collapse
|
5
|
Abstract
<P>Adenosine regulates a wide range of physiological functions through specific cell membrane receptors. On the basis of pharmacological studies and molecular cloning, four distinct adenosine receptors have been
identified and classified as A1, A2a. A2b and A3. These adenosine receptors are members of the
G-protein-coupled receptor family.
<P>
An intense medicinal chemistry effort made over the last 20 years has led to a variety of selective adenosine receptor agonists and antagonists. While all the agonists thus far identified are related to the adenosine structure, the antagonists available belong to different chemical classes. The prototypic antagonists are xanthine derivatives evolved from the natural compounds, caffeine and theophylline. Typically, they are 8-substituted-1,2,3-trialkylxanthine and are A1 selective antagonists. More recently, 8-styrylxanthines have been found to be selective for A2a receptors. Other non-xanthine heterocycles are potent A2a antagonists and possess different degree of selectivity. Selective antagonists are not available yet for A2b and A3 receptors.
<P>
Given the recent developments of A2a selective antagonists, we have reviewed their chemical structures and biological properties in the attempts to get insight into this emerging class of new interesting compounds. The development of some of the A2a antagonists will provide better understanding of the role of A2a receptors in physiological and pathological states. The compounds appear also to have the potential to be useful for the treatment of cerebral ischemia or neurodegenerative disorders, such as Parkinson's disease.</P>
Collapse
Affiliation(s)
- P.G. Baraldi
- Dipartimento di Scienze Farmaceutiche , Universita, di Ferrara, Via Fossato di Mortara
Ferrara, Italy
| | - B. Cacciar
- Dipartimento di Scienze Farmaceutiche , Universita, di Ferrara, Via Fossato di Mortara
Ferrara, Italy
| | - G. Spalluto
- Dipartimento di Scienze Farmaceutiche , Universita, di Ferrara, Via Fossato di Mortara
Ferrara, Italy
| | - A. Borioni
- Laboratorio di Chimica del Farmaco, lstituto Superiore di Sanita, Viale Regina Elena,
299, Roma, Italy
| | - M. Viziano
- Laboratori Ricerca, Schering-Piough, Comazzo, Milano, Italy
| | - S. Dionisotti
- Laboratori Ricerca, Schering-Piough, Comazzo, Milano, Italy
| | - E. Ongini
- Laboratori Ricerca, Schering-Piough, Comazzo, Milano, Italy
| |
Collapse
|